No Detail Found!

Efficacy and Toxicity of Concurrent Chemoradiation in Inoperable Oral Carcinoma in Pakistani Population.

Author(s)
Abdul Rehman Department of Radiation Oncology, Centre of Nuclear Medicine and Radiotherapy (CENAR), Quetta, Pakistan
Zafar Allaudin Department of Radiation Oncology, Institute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Hasan Nisar Faculty of Medical Science, Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad, Pakistan
Irfan Ullah Khan Department of Radiopharmacy, Institute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Ismat Fatima Department of Radiation Oncology, Institute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Amira Shami Department of Radiation Oncology, Institute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Misbah Masood Department of Radiation Oncology, Institute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Abubaker Shahid Department of Radiation Oncology, Institute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Abstract
Objective: To evaluate the efficacy of concurrent chemoradiation in patients with locally advanced inoperable squamous cell carcinoma of oral cavity in terms of local control and toxicity. Study Design: Case series. Place and Duration of Study: Institute of Nuclear Medicine and Oncology (INMOL), Lahore, from January 2008 to December 2013. Methodology: Sixty-nine patients with locally advanced inoperable oral cavity cancer, registered in INMOL hospital from January 2008 to December 2013 who fulfilled a pre-defined eligibility criteria, were enrolled in the study. Concurrent chemoradiation protocol consisted of conventional fractionation delivering 70 Gy with weekly Cisplatin (50 mg/m2) during the course of radiation. Tumor response was calculated by RECIST criteria version 1.1 along with the median overall survival and disease-free survival. Acute treatment related toxicities were graded as (G). Results: Thirty-six (52.17%) patients showed complete response; while 19 (27.54%), 8 (11.59%) and 6 (8.7%) were observed with partial response, stable and progressive disease, respectively. Treatment response was significant (p<0.001) in terms of responders vs. nonresponders to treatment. Median overall survival was 18.00 months; whereas, median disease-free survival remained 14.00 months. Main toxicities included mucositis (G3 and G4, 71%), xerostomia (G2 and G3, 82.5%), vomiting (G3 and G4, 51%), myelosuppression (G3 and G4, 26.2%), dermatitis (G3 and G4, 49.2%), and fatigue (G3 and G4, 57.9%). Conclusion: Platinum based CCRT remained effective for inoperable oral cancer patients.
Publication Details
Page(s) 342-347
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 27, Issue: 6, Year: 2017

Request the full text from PASTIC

References
FerlayJ,ShinHR,BrayF,FormanD,MathersC,ParkinDM, 2010.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,Int J Cancer 127 2893 -17
CamargoCM,VotiL,GuerraM,ChapuisF,MazuirM,CuradoMP, 2010.Oral cavity cancer in developed and in developing countries: Population-based incidence,Head Neck 32 357 -67
WeberRS,PetersLJ,WolfP,GuillamondeguiO, 1988.Squamous cell carcinoma of the soft palate, uvula, and anterior faucial pillar,Otolaryngol Head Neck Surg 99 16 -23
WeberRS,GidleyP,MorrisonWH,PetersLJ,HankinsP,WolfP, 1990.Treatment selection for carcinoma of the base of the tongue,Am J Surg 160 415 -19
D'Cruz,A , Lin,T , Anand,AK , Atmakusuma,D , Calaguas,MJ , Chitapanarux,I, 2013.Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines,Oral Oncology 49 872 -77
CrombieAK,FarahC,TripconyL,DickieG,BatstoneMD, 2012.Primary chemoradiotherapy for oral cavity squamous cell carcinoma,Oral Oncology 48 1014 -18
AdelsteinDJ,SaxtonJP,LavertuP,RybickiLA,EsclamadoRM,WoodBG, 2002.Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy,JCO 20 1405 -10
TeoM,KarakayaE,YoungCA,DykerKE,CoyleC,SenM, 2013.The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis,Clin Oncol 25 647 -53
ChenJH,YenYC,LiuSH,YaunSP,WuLL,LeeFP, 2016.Outcomes of induction chemotherapy for head and neck cancer patients: A combined study of two national cohorts in Taiwan,Medicine 95 e2845 -
AriyoshiY,ShimaharaM,OmuraK,YamamotoE,MizukiH,ImaiHCY, 2008.Epidemiological study of malignant tumors in the oral, maxillofacial region: survey of member institutions of the Japanese Society of Oral,Int J Clin Oncol 13 220 -8
KhanMH,NaushadQN, 2011.Oral squamous cell carcinoma in a 10-year-old boy,Mymensingh Med J 20 145 -50
DharPK,RaoTR,NairNS,MohanS,ChandraS,BhatKR, 2000.Identification of risk factors for specific subsites within the oral, oropharyngeal region - a study of 647 cancer patients,Indian J Cancer 37 114 -22
BourhisJ,AmandC,PignonJP, 2004.Update of MACH-NC (metaanalysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy,J Clin Oncol 22 5505 -
Taylor IVSG,MurthyAK,VannetzelJM,ColinP,DrayM,CaldarelliDD, 1994.Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer,JCO 12 385 -95
MaqboolLM,MalikTR,AfrozaF,KhanNA,HaqM,PatigarooAR, 2012.Treatment outcome with weekly cisplatin concurrent with radiation therapy in locally advanced head and neck squamous cell carcinoma,JIMSA 25 159 -61
AdelsteinDJ,LiY,AdamsGL,WagnerH,KishJA,EnsleyJF, 2003.An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer,JCO 21 92 -98
BernierJ,DomengeC,OzsahinM,MatuszewskaK,LefebvreJL,GreinerRH, 2004.Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer,N Engl J Med 350 1945 -52
CooperJS,PajakTF,ForastiereAA,JacobsJ,CampbellBH,SaxmanSB, 2004.Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck,N Engl J Med 350 1937 -44
SeiwertTY,SalamaJK,VokesEE, 2007.The chemoradiation paradigm in head and neck cancer,Nat Clinl Pract Oncol 4 156 -71
HugueninP,GlanzmannC,TausskyD,LutolfUM,SchmidS,MoeK., 1998.Hyperfractionated radiotherapy and simultaneous cisplatin for stage III and IV carcinomas of the head and neck. Long-term results including functional outcome,Strahlenther Onkol 174 397 -402
EspeliV,ZuccaE,GhielminiM,GianniniO,SalatinoA,MartucciF, 2012.Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer,Oral Oncol 48 266 -71
FabiA,BarduagniM,LauroS,PortaloneL,MauriM,MarinisF, 2003.Is delayed chemotherapy-induced emesis well managed in oncological clinical practice: An observational study,Support Care Cancer 11 156 -61
TerrellJE,FisherSG,WolfGT, 1998.Long-term quality of life after treatment of laryngeal cancer,Arch Otolaryngol Head Neck Surg 124 964 -71
BrowmanGP,HodsonDI,MackenzieRJ,BesticN,ZurawL, 2001.Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis,Head Neck 23 579 -89
AdelsteinDJ,SaxtonJP,RybickiLA,EsclamadoRM,WoodBG,StromeM, 2006.Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution,JCO 24 1064 -71
0

Citations

0

Downloads

136

Views